Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta™ (lefamulin), recently approved by the FDA for both Oral and IV use, and CONTEPO (fosfomycin) for injection. We resubmitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP). The FDA has assigned a PDUFA date of June 19,2020 for CONTEPO. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.
Events & Presentations